Therapeutics that enable life, uninterrupted

At Oruka, we apply state-of-the-art antibody engineering to validated modes of action to develop biologics with the potential to redefine the standard of care for psoriasis, psoriatic arthritis, and other indications.

Our lead programs, ORKA-001 and ORKA-002, are designed to block cytokines that play key roles in the pathogenesis of psoriasis and other inflammatory diseases. ORKA-001 targets the p19 subunit of interleukin-23 (IL-23p19) and ORKA-002 targets interleukin-17A and interleukin-17F (IL-17A/F). We have optimized ORKA-001 and ORKA-002 with the aim of perfecting the product profile we can offer and enabling patients to experience the greatest possible freedom from disease.

3D rendered monoclonal antibodies in varied shades of teal and blue.

To generate our development candidates, we optimize numerous antibody properties, including:

icon PK curve
Incorporating half-life extension technology to increase antibody exposure and reduce dosing frequency
Icon Specificity
Enhancing affinity and specificity to maximize potency and safety
Icon Optimization
Optimizing developability to ensure manufacturing consistency and enable convenient, high-dose formulations

Combining these features could allow more durable disease clearance for more patients

High-impact therapies that build on proven approaches

Our pipeline is anchored on two co-lead programs, which aim to treat and potentially modify disease by targeting mechanisms with proven efficacy and safety. They incorporate advanced antibody engineering, including half-life extension technology, to extend dosing intervals and potentially deliver best-in-class performance.

PROGRAM

Discovery

IND-Enabling

Clinical

Potential indications

IconORKA-001

IL-23p19
Psoriasis
  • Potentially best-in-class monoclonal antibody designed to inhibit IL-23p19 for the treatment of psoriasis
  • Engineered for extended circulation times while meeting or exceeding the performance and safety profiles of existing IL-23p19–targeted approaches
  • Potential to enable dosing as infrequently as once or twice a year

IconORKA-002

IL-17A/F
Psoriasis, psoriatic
arthritis, others
  • Potentially best-in-class monoclonal antibody designed to inhibit IL-17A/F for the treatment of psoriasis, psoriatic arthritis, and other conditions
  • Engineered for extended circulation times while meeting or exceeding the performance and safety profiles of existing IL-17A/F–targeted approaches
  • Potential to enable dosing as infrequently as two or three times a year

ORKA-003

Undisclosed

Collaborations that drive efficient innovation

Our pipeline of potentially best-in-class antibodies was discovered by Paragon Therapeutics, a team of world-class antibody discovery and engineering experts that is also the source of the technology behind Apogee Therapeutics and Spyre Therapeutics. We continue to collaborate to efficiently advance innovative therapeutics in pursuit of a new standard of care.